



REPLACEMENT SHEET

1/11





Fig. 1

REPLACEMENT SHEET

2/11

Fig. 2a


Pt 1



REPLACEMENT SHEET

3/11


Plasma & blood concentration levels (nmol/L)



REPLACEMENT SHEET

4/11

Plasma & blood concentration levels (nmol/L)




REPLACEMENT SHEET

5/11


Fig. 2d

Pt 4



REPLACEMENT SHEET

6/11



REPLACEMENT SHEET

7/11

Plasma & blood concentration levels (nmol/L)





Fig. 2f

REPLACEMENT SHEET

8/11

Plasma & blood concentration levels (nmol/L)






REPLACEMENT SHEET

9/11

Plasma & blood concentration levels (nmol/L)



REPLACEMENT SHEET

10/11

Plasma & blood concentration levels (nmol/L)




Fig. 3

As<sub>2</sub>O<sub>3</sub> Clinico-pathologic features and outcome of 12 consecutive patients with relapsed acute promyelocytic leukemia treated with oral

## REPLACEMENT SHEET

11/11

sex / age status	previous induction treatment	Time from relapse			Oral As <sub>2</sub> O <sub>3</sub> therapy			Latest PCR <sup>1</sup>	DFS	Remarks
		last CR	Hb	WBC	Plat	duration	additional Rx	result	Consolidation	
1° M / 23	R1 ATRA + Dauno i.v. As <sub>2</sub> O <sub>3</sub> + Ida	11 m	15.6	2.1	87	59 d	Ida	CR	Ida	13 m
2° M / 33	R2 Dauno / i.v. As <sub>2</sub> O <sub>3</sub> + Ida	10 m	14.0	2.5	25	76 d	ATRA	NR	-	+
3° F / 13	R2 ATRA + i.v. As <sub>2</sub> O <sub>3</sub>	25 m	13.4	2.1	20	32 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	(18 m) 19 m +
4 M / 54	R1 ATRA + Dauno	12 m	8.6	1.2	15	30 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	(18 m) 19 m +
5° M / 32	R1 ATRA + Dauno + MP	100 m	8.5	34.8	81	40 d	Ida	CR	Ida	(18 m) 18 m +
6 F / 32	R1 ATRA + Dauno	22 m	14.5	2.4	177	33 d	-	CR	Ida	(18 m) 18 m +
7° F / 45	R2 ATRA + Dauno / i.v. As <sub>2</sub> O <sub>3</sub> + Ida	12 m	12.2	0.8	84	51 d	-	CR	Ida	(18 m) 18 m +
8 F / 65	R1 ATRA	17 m	11.2	1.9	50	37 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	(14 m) 17 m +
9 F / 18	R2 ATRA + Dauno / i.v. As <sub>2</sub> O <sub>3</sub> + Ida	16 m	7.2	2.8	141	28 d	-	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	(12 m) 15 m +
10° F / 18	R1 ATRA + Dauno	12 m	10.1	1.9	180	28 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	(12 m) 14 m +
11° M / 45	R1 ATRA + Dauno	12 m	8.2	12.6	54	44 d	Ida	CR	Ida	(6 m) 9 m +
12 F / 40	R1 ATRA + Ara-c	240 m	4.2	0.6	9	22 d	-	CR	As <sub>2</sub> O <sub>3</sub>	(3 m) 7 m +

\*: pharmacokinetic data of oral As<sub>2</sub>O<sub>3</sub> have previously been reported<sup>6</sup>

1: PCR for *PML/RAR*, +: positive, -: negative, (time from initial diagnosis)

M: male; F: female, CR: complete remission; NR: non-remission; R1: first relapse; R2: second relapse

CBC: complete blood count; Hb: hemoglobin (g/dL); WBC: white blood cell count ( $\times 10^9/L$ ); Plat: platelet count ( $\times 10^9/L$ )

m: months; d: days; DFS: disease free survival

ATRA: all-trans retinoic acid; Dauno: daunorubicin; Ida: idarubicin; Ara-c: cytosine arabinoside

CA: carcinoma; AML: acute myeloid leukemia; CRF: chronic renal failure; DM: diabetes mellitus

CAPD: continuous ambulatory peritoneal dialysis; CRHD: chronic rheumatic heart disease; rep: replacement

CRF due to DM on CAPD,  
Ida consolidation omitted due  
to CRF  
Ida consolidation omitted due  
to high cumulative doses of  
anthracycline  
CRHD, double valve rep